11 Biotechnology Stocks to Buy Now

11 Biotechnology Stocks to Buy Now

This week, 11 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

TESARO, Inc. (TSRO) gets a higher grade this week, advancing from a D last week to a B. TESARO, Inc. develops and commercializes cancer therapeutics and supportive care products. For more information, get Portfolio Grader’s complete analysis of TSRO stock.

This is a strong week for XBiotech, Inc. (XBIT). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of XBIT stock.

CoLucid Pharmaceuticals, Inc.’s (CLCD) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of CLCD stock.

This week, Enzymotec Ltd.’s (ENZY) ratings are up from a C last week to a B. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ENZY stock.

Lion Biotechnologies, Inc. (LBIO) shows solid improvement this week. The company’s rating rises from a C to a B. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of LBIO stock.

MediciNova, Inc. (MNOV) earns a A this week, jumping up from last week’s grade of B. MediciNova, Inc. acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

This week, Opexa Therapeutics, Inc. (OPXA) pushes up from a C to a B rating. Opexa Therapeutics, Inc. develops cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, pancreatic, and cardiac conditions. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of OPXA stock.

The rating of Organovo Holdings, Inc. (ONVO) moves up this week, rising from a C to a B. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ONVO stock.

GlobeImmune, Inc. (GBIM) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of GBIM stock.

ArQule, Inc. (ARQL) boosts its rating from a C to a B this week. ArQule, Inc. is a biotechnology company that is engaged in the research and development of cancer therapeutics. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ARQL stock.

NanoViricides, Inc. (NNVC) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of NNVC stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/07/11-biotechnology-stocks-to-buy-now-3/.

©2019 InvestorPlace Media, LLC